Denosumab for Treatment of Hypercalcemia of MalignancyMimi I. Hu, Rajul K. Jain, Ilya Glezerman et al.|The Journal of Clinical Endocrinology & Metabolism|2014Cited by 200
Mutations in SLC34A3/NPT2c Are Associated with Kidney Stones and NephrocalcinosisDebayan Dasgupta, Clemens Bergwitz, Michaela Geßner et al.|Journal of the American Society of Nephrology|2014Cited by 172
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled PeriodAnthony A. Portale, Karl Insogna, Thomas O. Carpenter et al.|Calcified Tissue International|2019Cited by 160
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extensionKarine Briot, Erik A. Imel, Anthony A. Portale et al.|RMD Open|2021Cited by 72
Denosumab for Treatment of Hypercalcemia of Malignancy in Patients with Solid Tumors or Hematological Malignancies Refractory to IV Bisphosphonates: A Single-Arm Multicenter StudyMimi I. Hu, Howard Yeh, Rasim Gucalp et al.|Blood|2011Cited by 4